^
    2d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim)
    2d
    Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R (clinicaltrials.gov)
    P2, N=60, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    cytarabine • etoposide IV • idarubicin hydrochloride • Proleukin (aldesleukin) • busulfan • Neupogen (filgrastim)
    6d
    HSCT: Mozobil for Autologous Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=100, Recruiting, Thomas Jefferson University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Neupogen (filgrastim) • plerixafor
    13d
    hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov)
    P2, N=16, Recruiting, Leland Metheny | Suspended --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH2 mutation
    |
    temozolomide • carmustine • Neupogen (filgrastim)
    18d
    Persistent BCR::ABL1 p190 Minimal Residual Disease and Declining Donor Chimerism Following Haploidentical Bone Marrow Transplant in Pediatric Acute Myeloid Leukemia With Dual High-Risk Fusions. (PubMed, Cureus)
    Post-transplant recovery was marked by poor initial engraftment, requiring platelet transfusions and biweekly filgrastim...Despite hematologic recovery, qPCR consistently revealed persistent BCR::ABL1 p190 expression, indicating residual disease. This case underscores the challenge of eradicating leukemic stem cells (LSCs) in high-risk AML and supports the integration of next-generation flow cytometry for enhanced MRD and LSC assessment post-transplant.
    Journal • Minimal residual disease
    |
    ABL1 (ABL proto-oncogene 1) • RUNX1 (RUNX Family Transcription Factor 1) • CD34 (CD34 molecule) • MECOM (MDS1 And EVI1 Complex Locus)
    |
    Neupogen (filgrastim)
    22d
    RAFA: HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (clinicaltrials.gov)
    P2, N=70, Recruiting, Children's Hospital Medical Center, Cincinnati | Trial completion date: Jul 2027 --> Dec 2028 | Trial primary completion date: Jul 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
    24d
    Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • etoposide oral • vincristine • prednisone • Neupogen (filgrastim)
    29d
    Multidisciplinary Treatment for Cecal Cancer and Metachronous Liver Metastases in a Patient with Primary Autoimmune Neutropenia. (PubMed, Surg Case Rep)
    The administration of G-CSF to prevent neutropenia allowed the patient with AIN to safely undergo multidisciplinary treatment.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neupogen (filgrastim)
    1m
    Auto Stem Cell Transplant for Lymphoma Patients (clinicaltrials.gov)
    P2, N=150, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • CD4 (CD4 Molecule) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    ALK positive
    |
    cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Depocyte (liposomal cytarabine) • Neupogen (filgrastim)
    1m
    Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, University of Washington
    New P2 trial
    |
    Rituxan (rituximab) • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    1m
    Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • Neupogen (filgrastim) • dexrazoxane
    1m
    The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov)
    P1/2, N=260, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2027 --> Jun 2028
    Trial completion date
    |
    IGH (Immunoglobulin Heavy Locus) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • Neupogen (filgrastim)